Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin, Sirolimus and MMF for GVHD Prevention
NCT00506948Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2006
- Primary completion
- Oct 2010
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin, sirolimus, mycophenolate mofetil in graft-versus-host disease (GVHD), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2006; status: terminated.
02
Drugs
antithymocyte globulinsirolimusmycophenolate mofetil
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00506948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506948.